DOD Slow To Target Rising Rx Costs, Fraud Risks: Watchdog

Law360, Nashville (November 20, 2017, 8:25 PM EST) -- The U.S. Department of Defense’s health care arm had been too slow to respond to risks of fraud posed by drugs with rapidly rising costs, only recently updating its rules to cut down on those risks, according to a watchdog report Monday.

The Defense Health Agency had failed to respond in a timely manner to escalating prices on individual drugs, putting it at risk of fraudulent claims, the DOD Office of Inspector General said in its Nov. 16 report, made public Monday. This was despite already having a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.